Bavarian Nordic Announces Initiation of Safety and Immunogenicity Study of Ebola Vaccine Regimen in Sierra Leone
(Thomson Reuters ONE) -
* First study of the Ad26.ZEBOV/MVA-BN® Filo prime-boost vaccination regimen
in an Ebola outbreak country
* Study being initiated on parallel track with multiple ongoing Phase 1 and 2
studies across U.S., Europe and Africa to support licensure of the vaccine
regimen
COPENHAGEN, Denmark, October 9, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC:
BVNRY) announced today the initiation of a new clinical study of the Ebola
prime-boost vaccine regimen that combines Bavarian Nordic's MVA-BN(®) Filo
vaccine with the Ad26.ZEBOV vaccine from Crucell Holland B.V., one of the
Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The study
called 'EBOVAC-Salone' is being conducted in Sierra Leone's Kambia district,
where some of the country's most recent Ebola cases have been reported. The
first volunteers have received their initial vaccine dose.
The study, coordinated by the London School of Hygiene & Tropical Medicine and
sponsored by Janssen, is designed to evaluate the safety and immunogenicity of
the combination regimen. Volunteers will first be given the Ad26.ZEBOV dose to
prime their immune system, and then the MVA-BN Filo dose at a later date to
boost their immune response, with the goal of creating stronger and longer-
lasting immunity. The first stage of the study, which has now been initiated,
includes approximately 40 adults aged 18 years or older. In stage 2,
approximately 400 individuals across different age groups will be vaccinated,
including children and adolescents. Additional stages are being finalized in
consultation with the Sierra Leonean authorities and international health
agencies. Further details of the study can be found at
http://clinicaltrials.gov/ct2/show/NCT02509494.
Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic, said: "The
initiation of EBOVAC-Salone marks an important milestone for our joint program
with Janssen. It is a significant step forward in the development of a vaccine
against Ebola. It is remarkable how far the program has moved, which has only
been possible due to the commitment and dedication shown by both Janssen and our
employees in terms of the progress we have made in manufacturing bulk vaccine
for almost 2 million doses and initiating this study within a year of joining
forces. The key attributes of both the MVA-BN and Ad26 technologies were
initially recognized through NIH funding and subsequently the program has
benefited from additional governmental funding. We believe our progress to date
highlights the potential for a successful model of private-public partnerships
in the development of products addressing unmet medical needs for the future."
The EBOVAC-Salone study is being initiated on a parallel track with multiple
ongoing Phase 1 and 2 studies that are being conducted across the U.S., Europe
and Africa as part of the accelerated development plan for the Ebola vaccine
regimen. First-in-human Phase 1 clinical studies of the prime-boost vaccine
regimen began in the United Kingdom and United States in January 2015, followed
by several sites in Africa. In May 2015, Janssen presented positive preliminary
data from the UK Phase 1 study to the U.S. Food and Drug Administration. A Phase
2 study, being carried out in the UK and France, started in July 2015 with a
second multi-site Phase 2 study planned to shortly commence in several West and
East African countries.
With nearly 14,000 people infected by Ebola, Sierra Leone accounts for the
largest number of cases in any of the West African countries affected by the
outbreak that has raged since 2014. In total, more than 28,000 people have been
infected with the virus in the region and more than 11,000 people have died.
Although only few new cases have been reported over the past months, Sierra
Leone along with Guinea remains yet to be declared Ebola-free.
Contacts
Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43
Seth Lewis
Vice President Investor Relations (US)
Tel: +1 978 341 5271
About MVA-BN Filo
MVA-BN Filo is Bavarian Nordic's multivalent vaccine candidate designed to
protect against Ebola Zaire, Ebola Sudan and Marburg viruses. The vaccine
candidate was originally developed in collaboration with the U.S. National
Institute of Allergy and Infectious Diseases, part of the U.S. National
Institutes of Health (NIH) who also headed the preclinical investigation of the
Ad26.ZEBOV/MVA-BN Filo prime-boost vaccine regimen.
MVA-BN Filo is developed using Bavarian Nordic's proprietary vaccine platform
technology, MVA-BN, which is also employed in the Company's smallpox vaccine,
IMVAMUNE(® )(approved in EU and Canada under the trade name IMVANEX(®)). To-
date, Bavarian Nordic has produced and delivered 28 million doses of the
smallpox vaccine for emergency use to the U.S. Strategic National Stockpile.
In October 2014, Bavarian Nordic and Janssen entered into a global license and a
supply agreement for MVA-BN Filo. This was part of an overall commitment made by
Johnson & Johnson to accelerate and significantly expand the production of the
preventative Ebola vaccine program in development at its Janssen Pharmaceutical
Companies. To date, Bavarian Nordic has produced and delivered the bulk
equivalent of over one million doses of its vaccine to Janssen.
Funding acknowledgments
In January 2015, Europe's Innovative Medicines Initiative (IMI) awarded a
consortium of leading global research institutions and non-government
organizations working in conjunction with the Janssen Pharmaceutical Companies
grants totaling more than ?100 million from the Ebola+ program to support the
development, manufacturing and deployment of the vaccine regimen. The EBOVAC1
and EBODAC consortia partners also include the London School of Hygiene &
Tropical Medicine, University of Oxford, Inserm, Grameen Foundation and World
Vision of Ireland. The EBOVAC-Salone study is funded under Innovative Medicines
Initiative 2 Joint Undertaking grant agreement EBOVAC1 (grant no. 115854) and
EBODAC (grant no. 115847), part of the Ebola+ program launched in response to
the Ebola virus disease outbreak. This Innovative Medicines Initiative 2 Joint
Undertaking receives support from the European Union's Horizon 2020 research and
innovation program and EFPIA.
The investigational Ebola vaccine regimen was discovered in a collaborative
research program with the National Institutes of Health (NIH). This program
received direct funding and preclinical services from the National Institute of
Allergy and Infectious Diseases (NIAID), part of NIH, under Contract Numbers
HHSN272200800056C, and HHSN272201000006I and HHSN272201200003I, respectively.
The MVA-BN-Filo material used in phase 1 studies was produced under NIAID/Fisher
BioServices contract #FBS-004-009 and NIH contract HHSN272200800044C.
About Bavarian Nordic
Bavarian Nordic is a biopharmaceutical company focused on the development and
manufacturing of cancer immunotherapies and vaccines for infectious diseases.
Through a long-standing collaboration with the U.S. Government, Bavarian Nordic
has developed a portfolio of biological countermeasures, including the non-
replicating smallpox vaccine, IMVAMUNE(®), which is stockpiled for emergency use
by the U.S. and other governments. The vaccine is approved in the EU (under the
trade name IMVANEX(®)) and in Canada. Bavarian Nordic and its partner Janssen
are pioneering the development of an Ebola vaccine regimen, which has been fast-
tracked by authorities in response to the current situation in West Africa.
Additionally, in collaboration with the National Cancer Institute, Bavarian
Nordic has developed a portfolio of active cancer immunotherapies based on its
versatile pox-virus based technologies, including PROSTVAC(®), which is
currently in Phase 3 clinical development for the treatment of advanced prostate
cancer. The company has partnered with Bristol-Myers Squibb for the potential
commercialization of PROSTVAC. For more information visit www.bavarian-
nordic.com or follow us on Twitter (at)bavariannordic.
Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.
201528en:
http://hugin.info/100065/R/1957804/713357.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Bavarian Nordic A/S via GlobeNewswire
[HUG#1957804]
Unternehmensinformation / Kurzprofil:
Datum: 09.10.2015 - 08:00 Uhr
Sprache: Deutsch
News-ID 425962
Anzahl Zeichen: 10206
contact information:
Town:
Kvistgård
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 173 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic Announces Initiation of Safety and Immunogenicity Study of Ebola Vaccine Regimen in Sierra Leone"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
